Sanavia Oncology Inc.
June 18, 2025
Company Presentation
Oncology
153A
New epitopes to bind, more ways to fight, more patients to help.
Sanavia Oncology Inc. is a Series B stage, venture-backed, New York-based biotech company with a founding team from Rockefeller University, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Columbia University, Amgen, Genentech, Roche and Gilead. Sanavia’s pioneering epitope discovery technology finds novel cancer-specific epitopes in validated cancer targets that are present in majority of patients across multiple cancer types and pick the best epitope for ADC, CAR-T or T cell engagers. Sanavia combines proprietary in vivo immunization and antibody screening technology with Machine Learning and AI to pick the best functionally and structurally optimized ADC, CAR-T or T cell engager antibodies that bind to their epitope with atomic precision. Our SANA-01ADC targets a novel epitope present in 90% of lung, 75% of breast, 65% of ovarian, 50% of colon, 75% of pancreatic, and 55% of gastric cancers.
.png)
Company HQ City:
New York
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2021
Lead Product in Development:
SANA-01 ADC against solid tumors
CEO
Server Ertem
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
IND application and start of Phase I clinical trials
What is your next catalyst (value inflection) update?
in 12-18 months
Website
www.sanavia.bio
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}